Liquidia Corporation develops and commercializes therapies for respiratory and vascular diseases, with a focus on pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its updates center on YUTREPIA® (treprostinil) inhalation powder, the company’s PRINT® Technology-enabled approved therapy, along with L606, an investigational extended-release treprostinil formulation administered with a nebulizer, and generic Treprostinil Injection for PAH.
Recurring news includes financial results, YUTREPIA commercial uptake, clinical data presentations, pipeline studies, corporate presentations and investor conference participation. Company updates also discuss treprostinil delivery, PAH and PH-ILD treatment settings, cash generation and profitability as product sales become a larger part of Liquidia’s operating profile.
Liquidia (LQDA) entered a global settlement with United Therapeutics resolving all six pending lawsuits and preserving uninterrupted YUTREPIA access for PAH patients. Net payments total $380.7 million: $175 million to United Therapeutics within 30 business days, two $72.7 million installments due by January 31 and April 30, 2027, and $60.3 million to other parties in October 2026.
Liquidia agreed not to appeal the ruling that two patent claims covering treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) were valid and infringed. It submitted a supplement to remove PH-ILD from YUTREPIA’s label and stopped promotion for that indication. Preliminary, unaudited Q3 2026 YUTREPIA net product sales were $222.7 million; cash and equivalents totaled $396.1 million at September 30. Liquidia plans to continue its YUTREPIA and L606 clinical programs and has ended commercial support for Treprostinil Injection.
Liquidia (LQDA) received a District Court ruling that two asserted patent claims are valid and infringed by its YUTREPIA inhalation powder.
The Delaware court found claims 1 and 14 of U.S. Patent No. 11,826,327 valid and infringed; the remaining asserted claims were invalid. The parties must submit proposed judgments and remedies within one week. Liquidia plans to pursue appellate options and submit an FDA application supplement removing pulmonary hypertension associated with interstitial lung disease (PH-ILD) from YUTREPIA’s label. The remedy remains uncertain, potentially ranging from removal of that indication to broader restrictions on product availability. Potential outcomes and financial exposure cannot currently be reasonably estimated.
Liquidia (LQDA) received U.S. FDA Fast Track designation for YUTREPIA (treprostinil) inhalation powder to treat Raynaud's phenomenon associated with systemic sclerosis (SSc-RP). Fast Track status is intended for serious conditions with unmet medical need and may enable more frequent FDA interactions and rolling review.
SSc-RP affects up to 90% of systemic sclerosis patients, with 40%–60% developing digital ischemic ulcers and some progressing to amputation. No therapy is currently FDA-approved specifically for SSc-RP. Liquidia estimates about 30,000 U.S. patients have moderate to severe SSc-RP symptoms.
Liquidia plans to start RE-WARM (NCT07748000), a Phase 2a, randomized, open-label, dose-finding study of YUTREPIA in approximately 75 adults with SSc-RP at up to 30 U.S. sites. The study is expected to begin in October 2026 with primary completion targeted for February 2027 and will assess safety, pharmacodynamics and exploratory effects on attack frequency, severity and impact.
Liquidia (LQDA) will present two scientific posters at the European Respiratory Society (ERS) 2026 Congress in Barcelona, Spain, held September 5-9, 2026.
The first poster, from the ASCENT study (NCT06129240), covers baseline lung morphology patterns in interstitial lung disease with pulmonary hypertension and will be presented in Poster Session PS-35 on September 7, 2026, 8:00-9:30 CEST by N. Kolaitis (University of California, San Francisco, United States). The second poster describes the Phase 3 Re-Spire trial evaluating safety and efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in pulmonary hypertension with interstitial lung disease and will be presented in Poster Session PS-37 on September 8, 2026, 12:30-14:00 CEST by Prof. V. Cottin (Claude Bernard University Lyon 1, France).
Liquidia (NASDAQ:LQDA) announced that executives Michael Kaseta, Chief Operating Officer and Chief Financial Officer, and Jason Adair, Chief Business Officer, will provide a business update in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Boston on Tuesday, September 8, 2026 at 8:45 a.m. ET. Access to the live webcast and an archived replay for at least 30 days will be available via the Investors section of Liquidia’s website.
Liquidia (NASDAQ:LQDA) reported strong second quarter 2026 results driven by YUTREPIA (treprostinil) inhalation powder, with net product sales of approximately $170.4 million, up 31% from the first quarter of 2026, and its fourth consecutive quarter of profitability.
Total Q2 2026 revenue reached $171.7 million versus $8.8 million a year earlier, generating net income of $74.7 million and non-GAAP adjusted EBITDA of $96.3 million. Cash and cash equivalents increased to $284.2 million at June 30, 2026, from $190.7 million at December 31, 2025. Since launch in June 2025, YUTREPIA has received about 5,900 unique prescriptions, started treatment for more than 5,000 patients, with prescription-to-start conversion above 85%, and over 1,100 prescribers, while the company advances 10 clinical studies for YUTREPIA and L606.
Liquidia (Nasdaq:LQDA) will report its second quarter 2026 financial results on Wednesday, August 12, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time, with live and rebroadcast access available via its investor relations website for one year.
Liquidia (NASDAQ:LQDA) will present four posters at the PHA 2026 International PH Conference and Scientific Sessions in Dallas, June 11-14, 2026.
Posters cover ASCENT study data on YUTREPIA in PH-ILD, patient-reported cough, caregiver mental health, pharmacist roles, and an encore of safety and exploratory efficacy data.
Liquidia (Nasdaq:LQDA) announced its inclusion in the S&P SmallCap 600 Index, effective before market open on June 22, 2026. The index tracks 600 U.S. small-cap companies chosen by S&P Dow Jones Indices using market cap, liquidity, public float, and profitability criteria.
Liquidia (Nasdaq:LQDA) announced that CEO Dr. Roger Jeffs and COO/CFO Michael Kaseta will discuss the company’s business in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 3, 2026 at 12:45 p.m. ET. The live webcast and a 30-day replay will be available on the company’s investor relations website.